Where Mirv could grow | IMGN Message Board Posts


IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  53052 of 53272  at  12/3/2021 8:01:44 PM  by

wolingfeng


 In response to msg 53051 by  Bibliobiftek
view thread

Re: Where Mirv could grow

There is definitely label expansion opportunity. Obviously first of all Mirv needs to get approved by FDA. My guess is that if MIRASOL trial further confirms the benefit of Mirv monotherapy in PROC (meeting its primary endpoint hopefully), certain compendium like NCCN could even consider phase 2 trial, such as FORWARD II where they tested Bev + MIRV in both PROC and PSOC populations. That would further expand labeling into PSOC patients (still with high FRa), and later they may still be on monotherapy Mirv possibly since it's well tolerated.

And there are other later lines of therapy with different combo in PSOC. Unlikely Mirv will move to first line as you need very impressive activity/data to beat the first line SOC in a trial statistically. But you don't need to be a first-line agent to be a great drug.

IMGN 151 is only in the pre-clinical stage, still still many years away from commercialization even assuming everything goes smoothly. With more ADCs hopefully get approved by IMGN, certainly this could become a more valuable asset as they will have a track record of getting things done in the ADC arena.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 4  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...